Dr. Winton conducted the first bone marrow transplant at Emory University Hospital in 1979. Since that first transplant, Dr. Winton and the BMT team at Winship have made considerable contributions to continuing development of this process.
Titles and Roles
- Professor, Department of Hematology & Medical Oncology
- Emory University School of Medicine
- Medical Oncologist
- Research Program
- Discovery and Developmental Therapeutics
During his career on the Emory faculty, Dr. Winton’s research has focused on understanding normal and malignant hematopoiesis at the bench and bedside. At the bedside he has conducted clinical trials to test the effects of novel therapies and improved supportive care for treating myeloid malignancies, collaborated in establishing the first hematopoietic stem cell transplantation program in Georgia, and conducted studies to improve understanding of several hematologic disease entities (e.g. discovery of hemoglobin Atlanta, studies on large granular lymphocytic leukemia, frequent occurrence of copper deficiency masquerading as myelodysplasia). Laboratory and animal-based projects included methods to better quantify in vitro and in vivo granulopoiesis, granulopoietic growth factor perturbations during murine marrow regeneration, and the development of preclinical models for studying newly introduced recombinant human hematopoietic growth factors using the rhesus macaque.
Dr. Winton is a member of the American Society of Hematology and the American Society of Clinical Oncology.
Dr. Winton earned his Medical Degree from the University of Chicago Pritzker School of Medicine, where he completed his Internship as well. He then went on to complete his Residency and Fellowship at the Emory University Affiliated Hospitals.
Dr. Winton's primary clinical research continues to be focused on improving therapy for patients with myeloid malignancies. In recent years he has specialized in the non-BCR/ABL myeloproliferative neoplasms (MPNs) (polycythemi rubra vera, essential thrombocythemia, myelofibrosis) as well as rare granulocytic neoplasias such as systemic mastocytosis and eosinophilia. In 2008, Dr. Winton secured Winship Cancer Institute membership in the Myeloproliferative Disorder Research Consortium (MPD-RC), an NIH sponsored group of international clinical and basic scientists dedicated to improved understanding of the basic pathophysiology of MPNs and to the introduction and study of novel therapies. Several MPD-RC clinical trials are opened or soon to open and are accruing patients. All these studies include a state of the art tissue banking program. In 2009-2010, Dr. Winton collaborated in the pivotal phase III trial of the first-in-class JAK-2 inhibitor (Ruxolitinib, Incyte Corporation).
Below is a listing of current federal grants for the above principal investigator.
Publications Publication Date